Discussion on LYNPARZA

Written by patrippon on March 18, 2021.

When

03/18/21

6:00 pm - 7:00 pm

Virtual Expert Discussion on LYNPARZA® (olaparib)

Treatment of mCRPC with LYNPARZA:
An oral therapy for patients with HRR gene mutations following progression on enzalutamide or abiraterone

Presented by
Jacek Pinski, MD, PhD
Associate Professor of Medicine, Division of Medical
Oncology
USC/Norris Comprehensive Cancer Center
Los Angeles, California

To register or for more information, contact
Lynn Harris at 626-622-2658 or lynn.harris@astrazeneca.com